Teva Pharmaceutical Industries Limited (TEVA) Announces Launch of Generic Zemplar® in the United States  
10/1/2013 10:52:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to ZemplarĀ® (paricalcitol) tablets in the United States as of September 30, 2013. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

Help employers find you! Check out all the jobs and post your resume.